Kezar Life Sciences Q1 net loss $21.7M; cash $179.8M; clinical trials on track

Kezar Life Sciences, Inc.

2024-Q1 EPS reported -$0.30

Cash, cash equivalents and marketable securities totaled $179.8M as of March 31, 2024, down from $201.4M at Dec 31, 2023.
Net loss $21.7M ($0.30 per share) vs $22.2M ($0.31) in Q1 2023; R&D expenses $17.2M, G&A $6.5M.
PALIZADE Phase 2b for lupus nephritis actively enrolling; topline data expected mid-2026.
PORTOLA Phase 2a for autoimmune hepatitis enrolling; topline data expected mid-2025.
KZR-261 dose expansion in melanoma enrolling; initial study data expected by year-end 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kezar Life Sciences, Inc. reported first quarter ended March 31, 2024 results: net income $21.7 million, EPS $0.30 per basic and diluted common share.

Period: first quarter ended March 31, 2024
Net income: $21.7 million
EPS: $0.30 per basic and diluted common share
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2024 was $21.7 million, or $0.30 per basic and diluted common share

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056871

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.